Introduction
The pathogenetic basis for diabetic polyneuropathy (DPN) and its targeted treatment remain enigmatic, despite decades of intense investigations (66, 75, 76, 81) . However, several hyperglycemiainduced pathways have been identified such as 1) activation of the polyol pathway leading to redox imbalances, perturbation of myo-inositol and organic osmolyte imbalances (26, 53, 72); 2) nonenzymatic glycation yielding advanced glycation end-products; and 3) perturbations of neurotrophic homeostasis, particularly affecting NGF and the IGF-system (3, 55, 65, 77) . Many authors have proposed that these suggested consequences of hyperglycemia eventually come together causing mitochondrial dysfunction, superoxide over-production and oxidative and nitrosative stress which contribute to depletion of NO and impaired nerve perfusion and that this provides a common mechanism underlying the pathogenesis of DPN (5, 13, 58, 75) These synergistic pathogenetic mechanisms have however, almost exclusively been identified in streptozotocin-induced diabetes (STZ-D) in rats.
Moreover, the vascular hypothesis of DPN remains controversial and it is unclear whether similar neurovascular deficits exist in other animal models of diabetes.
During the last decade the concept has emerged that DPN differs metabolically, functionally and structurally in type 1 and type 2 diabetes in murine models that more closely mimic the human disorders (51, 59, 63, 67, 68) Besides hyperglycemia, increasingly the focus has turned to the pathogenetic roles of insulin and C-peptide deficiencies to explain the DPN accompanying type 1 diabetes (63, 84) . There is now evidence to suggest that insulin and C-peptide deficiencies are involved in early metabolic perturbations affecting neural Na + /K + -ATPase as well as the later occurring gene regulatory deficits involving neurotrophic factors and their receptors (50, 65, 84) . This may also be true for apoptotic phenomena afflicting both the peripheral and central nervous system in type 1 diabetes (36, 37, 70) . We have previously shown that replacement of insulinomimetic C-peptide in type 1 BB/Wor-rats is without any effect on hyperglycemia, but nevertheless improves chronic diabetic neuropathy and has preventive effects on suppressed nerve fiber regeneration in longstanding neuropathy (50, 63) . However, the mechanism(s) of this effect remain uncertain. In STZ-D rats, C-peptide replacement has been reported to improve nerve function by an NO-sensitive vascular mechanism (20). However, the effects of Cpeptide on other glucose-sensitive pathways critically implicated in DPN such as antioxidant defense systems were not reported.
The aims of this study were therefore two-fold: firstly to determine whether neurovascular dysfunction and increased oxidative stress were present in the insulinopenic type 1 BB/Wor-rat and secondly to determine the effects of C-peptide replacement on these end-points in this animal model.
The data were compared with those from isohyperglycemic and hyperinsulinemic C-peptide replete type 2 BBZDR/Wor-rats and non-diabetic BB-rats.
Material and Methods

Animals:
Sixty-seven type 1 pre-diabetic male BB/Wor-rats, 37 age-and sex-matched non-diabetes-prone BB-rats and 11 type 2 sex-matched BBZDR/Wor-rats were obtained from Biomedical Research Models (Worcester, MA). All animals were maintained in metabolic cages with free access to water and rat chow. Body weight, urine volume and glucosuria were monitored daily to determine onset of diabetes.
After onset of type 1 diabetes in BB/Wor-rats at 72±4 days of age, they were supplemented with titrated doses (0.5-3.5 U/day) of protamine zinc insulin (Novo Nordisk, Princeton, NJ). Blood glucose levels were measured every two weeks. Onset of type 2 diabetes in BBZDR/Wor-rats occurred at 75±3 days. BBZDR/Wor do not require insulin supplementation but maintain spontaneously hyperglycemic levels between 20-25 mmol/L, which is similar to the levels at which type 1 BB/Wor are maintained (64) .
At onset of diabetes, 30 type 1 BB/Wor-rats were started on rat II C-peptide (Genosys, Cambridge, UK) with a purity of more than 98% by HPLC. It was dissolved in saline (12 mg/ml) and administered via subcutaneously implanted osmopumps (Alzet Corporation, Palo Alto, CA), which delivered a minimum dose of 75 nmol C-peptide/kg body weight/day (63) . Experiment 1. In order to characterize changes in nerve oxidative defense enzymes, evaluate the effect of type 1 and type 2 diabetes on nerve blood flow, motor and sensory NCV's, and thermal pain thresholds, and explore the effects of C-peptide replacement on these deficits in type 1 diabetes, BB/Wor and BBZDR/Wor-rats were studied after 60 days of hyperglycemia, a time point when motor and sensory NCV slowing is well established (63) . The experimental groups consisted of: 1) nondiabetic control BB-rats (n=8); 2) untreated type 1 diabetic BB/Wor-rats (n=8); 3) diabetic BB/Wor-rats replaced with C-peptide (n=8) and untreated type 2 diabetic BBZDR/Wor-rats (n=7). After 2 months, diabetes was reconfirmed and motor and sensory NCVs, thermal thresholds and endoneurial nerve blood flow were measured. The rats were killed and sciatic nerves were rapidly excised and cleaned for biochemical measurements.
Experiment 2:
In order to explore whether the effects of C-peptide replacement were mediated by NO or a cyclooxygenase (COX) product, non-diabetic control BB rats (n=29) and untreated (n=29) and Cpeptide-replaced (n=22) BB/Wor-rats were treated with L-NAME, flurbiprofen, or L-NAME + flurbiprofen administered in drinking water. L-NAME and/or flurbiprofen were administered for the final 2 wk of the 2 month experimental period in both nondiabetic control BB-rats and untreated or C-peptide treated BB/Wor rats. Non diabetic animals were given drinking water containing 0.685 mM L-NAME [a competitive inhibitor of NO synthase (54) ] , whereas in diabetic animals the concentration was reduced to 0.137 mM, to compensate for the 5 fold increase in water consumption. Flurbiprofen (a nonselective COX 1 & 2 inhibitor, relative COX-2 vs. COX-1 IC 50 5-10 (23, 41) ) was administered at a dose of 6 mg/kg/day with the concentration of flurbiprofen reduced to 20% in diabetic animals (5:1) in order to compensate for their increased water consumption.
After 2 weeks, diabetes was reconfirmed and NCV's, thermal thresholds and nerve blood flow were measured. The rats were killed and both sciatic nerves were rapidly excised and cleaned for biochemical measurements.
Nerve conduction velocities:
Nerve conduction velocity measurements were performed non-invasively under temperature controlled conditions (36-38°C). Animals were sedated by inhalation of Metafane (Pitman-Moore, Mundelein, IL). For motor nerve conduction velocity (MNCV), the left sciatic nerve was stimulated with square pulses (2 Hz) at the sciatic notch and the tibial nerve at the ankle by supramaximal (8V) stimulations. The evoked motor responses were recorded from the first interosseous muscle. Eight to sixteen recordings were computer-averaged. MNCV was calculated by dividing the distance between the two stimulating points by the difference between proximal and distal latencies (63) . Sensory nerve conduction velocity (SNCV) was recorded in the right hind-limb. The digital nerves of the second toe were stimulated with square pulses of 0.05 msec duration using supramaximal current intensities.
Sensory nerve action potentials were recorded from posterior to the medial malleolus. The distance between stimulating and recording electrodes was 25 mm and that between the active recording and indifferent electrodes was 10 mm. Eight to sixteen responses were averaged. The distance between the stimulating and active recording electrodes was measured and divided by the latency to the peak of the initial negative deflection (64) .
Thermal plantar test
Hyperalgesia to thermal stimulation was measured using a UGO Basile Biological Research Apparatus (Comerio, Italy) and performed according to Hargreaves, et al (30) . Animals were placed in a clear plastic chamber with an elevated plastic bottom and allowed to acclimate for 5 min. A mobile thermal stimulator, generating infrared energy of constant heat intensity, was positioned under the posterior plantar area of a hind paw. The time from heat source activation to the animal's selfwithdrawal of the hind paw was recorded in seconds. This was repeated six times with 5 minute intervals between measurements of alternating hind paws. The mean of these measurements was used as the measure of the latency (83) .
Measurement of endoneurial nutritive nerve blood flow by H 2 clearance
Nutritive nerve blood flow was assessed by H 2 clearance as previously reported (52). Animals were anesthetized with an i.p. injection of inactin (65-85 mg/kg). The left carotid artery was cannulated with polyethylene tubing and patency maintained with heparinized saline (50 U/ml normal saline). The catheter was connected to a transducer and the blood pressure monitored by a MacLab data acquisition system. A tracheostomy was performed and the animals were artificially respired with O 2 :N 2 (21%:79%) using a small animal ventilator (Harvard Apparatus, South Natick, MA). Core body temperature was monitored by a rectal probe, and hind limb muscle temperature by a needle probe inserted into the muscle layer; and both were maintained at 37 0 C by a Homeothermic Blanket Control Unit (Harvard Apparatus, South Natick, MA). The right sciatic nerve was exposed and gently dissected away from the surrounding tissue. The skin around the incision was positioned to create a reservoir. A ground electrode was inserted subcutaneously into the flank of the rat. Using a micromanipulator, a hydrogen-sensitive platinum electrode (tip diameter 1-2 µm; World Precision Instruments, Sarasota, FL) was inserted into the nerve above the trifurcation. Mineral oil at 37°C was used to fill the reservoir and prevent diffusion of gases out of the nerve. Oil temperature was monitored and maintained at 37°C by radiant heat. The nerve was polarized with 0.25V, and when a stable baseline was achieved, the animal received a gas mixture containing 10% hydrogen which was continued until the current change stabilized (10-30 min), at which time hydrogen flow was terminated. Current recordings were made every 30 s until baseline levels were achieved (30-60 min). After the experiment, mono-or biexponential clearance curves were fitted to the data (Graphpad Software, La Jolla, CA). Nutritive endoneurial nerve blood flow was taken as the slow component of the curve. An average of two determinations at different sites was used to determine nutritive endoneurial nerve perfusion.
Nerve biochemical measurements
Malonyldialdehyde (MDA) plus 4-hydroxylalkenal (4-HA).
Measurements of total MDA and 4-hydroxyalkenal levels were performed using commercially available kits (Oxis International, Inc., Portland, OR [LPO-586 assay]). The method is based on the reaction of a chromogenic reagent, N-methyl-2-phenylindole, with MDA and 4-HA at 45°C [47] . The samples were prepared by homogenization of pre-weighed nerve segments (~40mg) in 1 ml of 20 mM tris-buffer, pH 7.4 containing 5 mM butylated hydroxytoluene. Two hundred microliter of homogenate was used for measurements of total MDA and 4-HA levels according to the procedure described in detail in the kit. The absorbance of chromogenic product was measured at 586 nm (spectrophotometer Beckman DU 640) and was compared with the absorbance in corresponding 4-HA standards.
GSH
Approximately 15-20 mg of the sciatic nerves were weighed, homogenized in 1 ml of ice-cold 6% HCIO 4 , and centrifuged at 4000 x g for 10 min. After centrifugation, the samples were immediately neutralized with 5M K 2 CO 3 to pH 6-7 and centrifuged again at 4000 x g for 5 min to precipitate insoluble KClO 4 . Reduced glutathion (GSH) levels were assayed in perchloric extracts spectrofluorometrically. In brief, 0.1 ml of extract was mixed with 0.89 ml of 20 mM EDTA in 1.0M
tris-HCl buffer (pH 8.1), and the reaction was initiated by the addition of 0.01 ml of 1% methanol solution of O-phthaldialdehyde.
Catalase
Catalase enzyme activity was measured fluorometrically by using a kit (cat. #A-22180; Molecular Probes, Inc, Eugene, OR). Samples were allowed to react with H 2 O 2 followed by reaction with the chromagen Amplex™ Red. The chromagen is oxidized by any residual unreacted H 2 O 2 to produce an absorption peak at 587 nm. As the amount of catalase in the unknown increases, the amount of signal from the chromagen decreases, allowing measurement of catalase enzyme activity when compared against a catalase standard curve. Briefly, tissues were rapidly dissected, washed in ice cold PBS and snap frozen in liquid nitrogen until ready for assay. Tissues were then thawed and homogenized in 50 mM NaH 2 PO 4 pH 7.4 buffer on ice and clarified by centrifugation (10,000 x g , 4˚ C, 15 min). Supernatants were reacted with H 2 O 2 followed by Amplex™ Red. The amount of catalase activity was measured fluorometrically at Abs/Em 563/587. Absolute activity was calculated by comparing unknowns against a catalase standard curve.
Superoxide Dismutase
Cu/Zn-superoxide dismutase (SOD) enzyme activity was measured by using a kit (#21010; Oxis International, Inc.). Briefly, tissues were rapidly dissected, washed in ice cold PBS and snap frozen in liquid nitrogen until ready for assay. Tissues were then thawed and homogenized in PBS on ice, and clarified by centrifugation (10,000 x g, 4˚ C, 15 min). SOD decreases the autoxidation rate of the chromagen (5,6,6a,11b-tetrahydro-3,9,10-trihydroxybenzo[c]fluorene). Therefore, supernatants were reacted with chromagen and optical density was spectrophotometrically measured at 525 nm over time to calculate SOD enzyme activity rate.
In all studies, investigators performing the measurements were unaware of treatment-group assignments. The animal study protocols were approved by Wayne State University and the University of Michigan Committees on Use and Care of Animals.
Statistical analysis
Data are expressed as mean ± SEM. Differences among experimental groups were determined by ANOVA, and the significance of between-group differences assessed by Student-Newman-Keuls multiple range test. Significance was defined as p≤0.05. If the variances for the variables were found to differ significantly, a logarithmic transformation was performed which corrected the unequal variances.
All analyses were then performed on the transformed data.
RESULTS
Effects of diabetes and C-peptide on plasma glucose values and body weights (Experiment 1, Table 1)
After two months of diabetes, body weights were 17% lower in BB/Wor-rats vs. control rats (p<0.001), and 54% higher in BBZDR/Wor-rats vs. control rats (p<0.001). Body weights were unaffected by C-peptide treatment. Blood glucose levels were elevated ~4-5 fold in all diabetic rat groups. Serum insulin levels were markedly decreased in BB/Wor-rats (p<0.001) and increased in BBZDR/Wor-rats (p<0.01). C-peptide replacement of BB/Wor-rats did not alter weight, hyperglycemia, required daily insulin dosing, or plasma insulin levels, but completely normalized circulating C-peptide levels.
C-peptide replacement ameliorates motor and sensory NCV slowing and thermal hyperalgesia in BB/Wor-rats (Experiment 1, Fig 1) After two months of diabetes, as expected, MNCV and SNCV were reduced by 22% and 14%, respectively (p<0.001) in BB/Wor vs. nondiabetic control rats. The administration of C-peptide partially prevented MNCV deficits by 72% (p<0.05) and completely prevented SNCV deficits. In response to thermal heating, limb withdrawal time was decreased by 42% (p<0.001) in BB/Wor-rats, and was partially corrected by C-peptide (39%; p<0.05).
In contrast, MNCV was decreased by only 5% (p<0.05) in BBZDR/Wor-rats vs nondiabetic control animals, and SNCV was unaltered. Plantar heat withdrawal thresholds were not significantly affected in BBZDR/Wor-rats. Fig. 2 ).
In BB/Wor-rats, endoneurial blood flow was reduced by 44% (p<0.01) vs. control rats. C-peptide treatment of BB/Wor-rats, prevented the endoneurial perfusion deficits (endoneurial perfusion increased by 58%, p<0.05 vs untreated BB/Wor-rats). In parallel, endoneurial blood flow was decreased by 33%
in BBZDR/Wor rats (p<0.01). Mean arterial blood pressure was significantly reduced in BB/Wor-rats compared to controls (119±16 vs 142±7 mmHg respectively, p<0.05) but was unchanged in BB/Z animals (142±18 mmHg). The results were not significantly affected after correction for blood pressure and expressed as vascular conductance.
Antioxidant defense is impaired and lipid peroxidation is increased in BB/Wor and BBZDR rats
(Experiment 1, Table 2 )
Nerve MDA plus 4-HA concentration was 2.3 fold (p<0.01) higher in BB/Wor-rats compared to nondiabetic control animals. The diabetes-induced increase in lipid peroxidation was unaffected by Cpeptide treatment. SOD activity was decreased by 49% (p<0.01) in these rats compared to control animals and also unaffected by C-peptide treatment. Similarly, catalase activity was decreased by 53% (p<0.05) in BB/Wor rats and unaffected by C-peptide.
In BBZDR/Wor-rats, MDA plus 4-HA concentration was increased by 2.8 fold (p<0.01), SOD activity was unchanged, whereas catalase activity was decreased by 45% (p<0.05). Nerve GSH levels were not significantly changed in any of the experimental groups.
Effects of L-NAME and flurbiprofen, on body weight and plasma glucose (Experiment 2)
Neither L-NAME nor flurbiprofen alone or in combination effected body weights in nondiabetic or untreated or C-peptide treated BB/Wor-rats (data not shown).
Effect of L-NAME and flurbiprofen, on MNCV, SNCV and thermal hyperalgesia (Experiment 2, Table 3 )
After 2 weeks, neither L-NAME nor flurbiprofen nor a combination of the two, affected MNCV, SNCV nor thermal hyperalgesia in nondiabetic control rats. In non-C-peptide-treated BB/Wor-rats L-NAME improved partially, but significantly (18% p<0.05), the latency of thermal hyperalgesia. In C-peptide treated BB/Wor-rats, L-NAME eliminated partially the effect of C-peptide on MNCV (48%, p<0.001) and SNCV (54%, p<0.01). L-NAME had no effect on thermal hyperalgesia in C-peptide treated BB/Wor-rats. Flurbiprofen had no effects on either MNCV, SNCV or thermal hyperalgesia in C-peptide treated rats.
L-NAME but not flurbiprofen reverses the effect of C-peptide on endoneurial nutritive NBF (Experiment 2, Table 4 ).
In L-NAME, flurbiprofen and L-NAME+ flurbiprofen treated nondiabetic control rats, endoneurial blood flow was reduced by 30%, 23% and 27% respectively, p<0.05 vs. untreated nondiabetic rats. In BB/Wor-rats, the diabetes-induced deficit of endoneurial perfusion was not affected by L-NAME nor flurbiprofen. In BB/Wor-rats, L-NAME, but not flurbiprofen completely prevented the protective effect of C-peptide on endoneurial blood flow. As expected, mean arterial blood pressure was significantly increased in all the L-NAME treated animal groups, but was unaffected by flurbiprofen. These results were not affected after correction for blood pressure and expressed as vascular conductance. Decreased endoneurial perfusion has emerged as an important contributing factor to the development of motor NCV slowing in experimental diabetes based upon the findings in STZ-D rats (53, 75). Decreased nerve blood flow and consequent endoneurial hypoxia are thought to contribute to NCV slowing by promoting nerve energy deficits (74, 75) . This report is the first to demonstrate in the type 1 BB/Wor-rat, that endoneurial perfusion is also decreased in concert with NCV slowing. Type 2 hyperinsulinemic BBZDR/Wor-rats also exhibited a significant decrease in endoneurial blood flow.
However, despite 2 months of hyperglycemia, motor NCV was only minimally slowed and sensory NCV and thermal latencies were unaffected in this model, suggesting that reduced endoneurial perfusion does not necessarily result in NCV slowing or hyperalgesia. In this type 2 animal model longer durations of diabetes are required to develop more profound nerve conduction deficits (a 17% reduction of NCV has been observed after 14 months of diabetes (64)). Moreover, in BBZDR/Wor-rats, reduced nerve perfusion was observed despite the absence of C-peptide depletion, suggesting that endoneurial In nondiabetic control animals, 2 wks treatment with both L-NAME and/or flurbiprofen decreased endoneurial perfusion, without affecting NCV, demonstrating that acute reductions in nerve perfusion alone are not sufficient to produce electrophysiological deficits. We have previously reported that more chronic (3 month) treatment with L-NAME is required to slow NCV in nondiabetic Wistar rats (72) . However, the beneficial effects of C-peptide on neurovascular perfusion and NCV slowing were reversed by the simultaneous treatment with L-NAME but not flurbiprofen, implicating an NO but not COX-mediated mechanism. We have previously reported the ability of L-NAME to specifically competitively inhibit NOS in experimental type 1 diabetes, since its effects on NCV slowing and blood pressure elevation can be prevented by arginine supplementation (72) . The sensitivity of the effect of Cpeptide to L-NAME is consistent with other interventions, which appear to work via NO including ARIs (11, 72), evening primrose oil (11), acetyl L-carnitine (19) , salbutamol and doxazosin (18) .
The effects of diabetes on NO metabolism and precise location of the critical NO effect appear to be complex. NO synthase the enzyme catalyzing the conversion of L-arginine to citrulline and NO at the expense of NADPH (43) is situated at sites critical for the regulation of neurovascular function including endothelial cells, vascular smooth muscle cells, and sympathetic ganglia (75) . In sympathetic ganglia, immunohistochemical staining has shown a reduction of NO synthase stainability in diabetic rats (60) . In the sympathetic autonomic nervous system, NO may inhibit sympathetic tone (61) such that impaired NO synthase activity in diabetes may increase sympathetic outflow resulting in neurovascular dysfunction. Alternatively, depletion of NO in the vasa nervorum has been invoked as a critical factor in the development of nerve perfusion deficits (11, 75). Impaired synthesis of NO has been linked to polyol pathway activation through an NADPH-mediated mechanism and alterations in protein kinase activation and calcium levels (8, 27, 72) . Additionally, increased oxidative stress has been implicated in the depletion of vascular NO (31, 75) . Conversely, human studies have demonstrated elevated plasma levels NO3-in subjects with advanced neuropathy (40) and increased plasma nitrotyrosine, an indirect marker of pro-oxidant peroxynitrite formation (32) , has been identified in diabetic patients (15) . In animal models of EDN, increased peroxynitrite formation has been implicated in cell death (22).
Therefore the effects of diabetes on NO metabolism appear complex, highly compartmentalized and critically affected by oxidative stress. Although our data clearly indicate NO repletion in the beneficial effects of C-peptide, which is consistent with other reports (25, 33, 35) , the mechanism of this effect is unclear, since C-peptide does not alter polyol pathway flux (63) The precise mechanisms whereby hyperglycemia/insulin/C-peptide depletion contributes to hyperalgesia remains unclear. Oxidative stress has been invoked as a contributing factor to hyperalgesia (14, 78) and abnormal calcium signaling in the DRG neurons of diabetic rodents (29, 79) and consequent activation of NO/cGMP/PKG pathways has been invoked in the pathogenesis of experimentally-induced pain (42, 69) . Our demonstration that L-NAME treatment of BB/Wor-rats attenuated hyperalgesia is consistent with other reports implicating NO as a second messenger system contributing to hyperalgesia (2) . The persistent effect of C-peptide on hyperalgesia despite L-NAME co-treatment, the absence of a C-peptide effect on oxidative stress, and the lack of hyperalgesia in BBZDR/Wor-rats, implies that neurovascular deficits, oxidative stress and NO are not involved in this effect. In BB/Wor-rats, degeneration of nociceptive C-fibers is associated with decreased expression of NGF, substance P and CGRP in DRG neurons, which are prevented by C-peptide (Murakawa and Sima, unpublished data), implicating a neutrophic/neuropeptide-sensitive mechanism. Further studies are required to characterize these effects. (46, 47) nerve lipid peroxidation products were increased in both BB/Wor and BBZDR/Wor models after 2 months of hyperglycemia. However, differences emerged in the response of the antioxidant defense enzymes, since GSH was not depleted in either animal model, and SOD activity (but not catalase) was preserved in BBZDR/Wor-rats. The presence of increased lipid peroxidation but lack of GSH depletion parallels the findings in some diabetic mouse models of DPN (Stevens M and Obrosova IG, personal observations), but is in contrast to the STZ-D rat (46, 47) and suggests nonuniformity in the diabetic rodent response to oxidative stress. Whether disruption of other antioxidant defense systems such as the ascorbate/dehydroascorbate or taurine systems is of greater importance in these animal models, and the precise loci of the critical oxidative insult remain to be explored. Nevertheless, these heterogeneous responses in different animal models may aid understanding of the mechanisms contributing to and protecting from oxidative stress in diabetes.
In summary, the present study has demonstrated that endoneurial perfusion is decreased and oxidative stress increased in type 1 BB/Wor-rats. C-peptide replacement did not effect oxidative stress, but nevertheless prevented NCV and neurovascular deficits and attenuated thermal hyperalgesia, by NO- Table 1 . Clinical data of control, type 1 diabetic BB/Wor-rats, type 1 C-peptide replaced BB/Wor-rats and type 2 BBZDR/Wor-rats. C-peptide replacement had no effect on body weight, blood glucose levels, or required daily insulin dose in BB/Wor-rats. Type 2 BBZDR/Wor-rats were significantly (p<0.001) heavier than control and BB/Wor-rats, but showed hyperglycemic levels equal to those in BB/Wor-rats and C-peptide replaced BB/Wor-rats. C-peptide replacement of BB/Wor-rats had no effect on plasma insulin levels, and normalized fully plasma C-peptide levels. Insulin levels were significantly (p<0.01) higher in type 2 BBZDR/Wor-rats compared to BB/Wor-rats.
*: p<0.01, **: p<0.001 vs control group. Table 3 . Neither L-NAME (+L) or flurbiprofen (+F) or the two combined (+L+F) had any effect on nerve conduction velocities and thermal hyperalgesia latencies in control rats (A).
M. J. Stevens et al.: C-peptide corrects endoneurial blood flow
In non-C-peptide-treated BB/Wor-rats L-NAME improved partially but significantly (p<0.05) the latency of thermal hyperalgesia (B). In C-peptide treated BB/Wor-rats L-NAME eliminated partially the effect of C-peptide on MNCV (p<0.001) and SNCV (p<0.01). L-NAME had no effect on thermal hyperalgesia in C-peptide treated BB/Wor-rats. Flurbiprofen had no effects on either MNCV, SNCV or thermal hyperalgesia in C-peptide treated rats(C Table 4 . Effect of L-NAME and flurbiprofen on endoneurial nutritive nerve blood flow (Experiment 2). Table 4 . Endoneurial NBF was assessed by hydrogen clearance technique as described in Methods. All flow data were also expressed as vascular conductance, which was calculated by dividing the blood flow by the mean systemic blood pressure over the recording period. Data shown are mean ± 1 SEM. Cont BB/Wor BB/Wor+C BBZDR/Wor n=6 n=7 n=6 n=7
Group
